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Abstract
Background: Oxaliplatin, a platinum-based chemotherapy utilised in the treatment of colorectal cancer, produces two
forms of neurotoxicity- acute sensorimotor neuropathic symptoms and a dose-limiting chronic sensory neuropathy. Given
that a Na
+ channelopathy has been proposed as the mechanism underlying acute oxaliplatin-induced neuropathy, the
present study aimed to determine specific mechanisms of Na
+ channel dysfunction.
Methodology/Principal Findings: Specifically the function of transient and persistent Na
+ currents were followed during
treatment and were investigated in relation to oxaliplatin dose level. Eighteen patients were assessed before and after a
single oxaliplatin infusion with motor and sensory axonal excitability studies performed on the median nerve at the wrist.
While refractoriness (associated with Na
+ channel inactivation) was significantly altered post-oxaliplatin infusion in both
motor (Pre: 31.766.4%; Post: 68.8614.5%; P#.001) and sensory axons (Pre: 31.465.4%; Post: 21.465.5%; P,.05), strength-
duration time constant (marker of persistent Na
+ conductances) was not significantly altered post-infusion (Motor Pre:
0.39560.01 ms; Post: 0.39460.02 ms; NS; Sensory Pre:0.54460.03 ms; Post: 0.53560.05 ms; NS). However, changes in
strength-duration time constant were significantly correlated with changes in refractoriness in motor and sensory axons
(Motor correlation coefficient=2.65; P,.05; Sensory correlation coefficient=.67; P,.05).
Conclusions/Significance: It is concluded that the predominant effect of acute oxaliplatin exposure in human motor and
sensory axons is mediated through changes in transient rather than persistent Na
+ conductances. These findings are likely
to have implications for the design and trial of neuroprotective strategies.
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Introduction
Oxaliplatin is a third generation platinum-based chemotherapy
effective in the treatment of colorectal cancer [1,2,3]. Oxaliplatin
treatment is limited by prominent neurotoxicity which develops
immediately following infusion and accumulates across treatment
[4]. Immediately following infusion, acute neuropathic symptoms
develop in the majority of patients, consisting of cold-induced
paresthesia, fasciculations and cramps which typically resolve
within a week following infusion [5,6]. With increasing cumulative
dose, a chronic sensory neuropathy develops, leading to long-
lasting functional disability [1,4].
Recent experimental studies across a variety of models have
suggested that oxaliplatin modulates axonal voltage-gated Na
+
channels, specifically by slowing Na
+ channel inactivation kinetics
[7–9], shifting the voltage dependence of inactivation to more
negative membrane potentials [10], or reducing Na
+ current
[10,11]. However, there remains no consensus about the
mechanisms underlying the development of an acute ‘‘Na
+
channelopathy’’ in oxaliplatin treated patients, with in vitro studies
inconsistent to date concerning the relative involvement of
transient and persistent Na
+ conductances [9,11].
In previous studies, our group has identified striking changes in
Na
+ channel related parameters [12–15], however there has been no
assessment of the relative contributions of Na
+ conductance subtypes
in both motor and sensory axons in the development of acute
oxaliplatin-induced neurotoxicity. As Na
+ channel modulation
remains a potential neuroprotective strategy for oxaliplatin-induced
neurotoxicity, it is important to investigate the specific types of Na
+
conductances targeted by oxaliplatin. The present study utilised novel
functional and specialised neurophysiological approachesto assessthe
effects of acute oxaliplatin administration on markers of axonal
transient and persistent Na
+ conductances and determined the dose-
response relationship of oxaliplatin on Na
+ currents in vivo.
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Participants
Eighteen patients treated with oxaliplatin for colorectal cancer
were prospectively assessed before and immediately following
oxaliplatin infusion. Three of these patients were included in a
prior study [15]. Patients received standard oxaliplatin containing
treatment regimens with initial oxaliplatin doses ranging from
85–130 mg/m
2 given every 2 to 3 weeks for a total of 6–12
treatment cycles. Oxaliplatin (FOLFOX 4 regimen: 85 mg/m
2,
FOLFOX 6 regimen: 100 mg/m
2) was infused every 2 weeks in
conjunction with leucovorin (200 mg/m
2) and followed by bolus
5-fluorouracil (5-FU; 400 mg/m
2). For the next 48 hours, a
continuous infusion of 5-FU (600 mg/m
2) was given, followed by
leucovorin (200 mg/m
2) and 5-FU bolus (400 mg/m
2) on the 2
nd
day [2,16]. In patients receiving XELOX regimens, oxaliplatin
(130 mg/m
2) was given intravenously every 3 weeks with oral
capecitabine (1000 mg/m
2) twice daily for 2 weeks [17].
Ethics
The study was approved by the South Eastern Area Health
Service (Eastern Section) Human Research Ethics Committee and
University of New South Wales Human Research Ethics
Committee. Participants provided written informed consent in
accordance with the declaration of Helsinki.
Study Design and Objectives
Each patient was assessed once immediately prior to oxaliplatin
infusion and once immediately following the same infusion to
compare the changes pre- and post-infusion.
Patients were tested in treatment cycles from the 2
nd treatment
to the 6
th treatment, corresponding a cumulative dose range of
200–650 mg/m
2 oxaliplatin. For analysis, patients were divided
into groups based on cumulative oxaliplatin dose (less than or
greater than 400 mg/m
2) as prior studies highlighted the changes
in acute excitability parameters after this dose level [14,15].
Clinical Neurotoxicity Grading Scales
To assess the extent of acute neuropathic symptoms, the
Oxaliplatin-Specific Neurotoxicity Scale (OSNS) was utilized with
the following grades: Grade 1 – dysesthesia or paresthesia that
completely regresses before the next cycle of therapy; Grade
2 – dysesthesia or paresthesia persisting between courses of
therapy; and Grade 3 - dysesthesia or paresthesia causing
functional impairment [18]. In addition the Neuropathy Sensory
Subscale of the National Cancer Institute (NCI) Common Toxicity
Criteria for Adverse Events Scale (Version 3) was utilized with the
following grading system: Grade 1 (Mild) – loss of deep tendon
reflexes or paresthesia not interfering with function; Grade 2
(Moderate) – sensory alteration or paresthesia interfering with
function but not activities of daily living; Grade 3 (Severe) –
sensory alteration or paresthesia interfering with activities of daily
living; and Grade 4 – disabling [19].
Neurophysiological Techniques
Multiple excitability studies were undertaken, utilising previ-
ously described protocols [20,21] and threshold tracking Qtrac
software ( Institute of Neurology, London, UK). Compound
muscle action potentials (CMAPs) were recorded from the
abductor pollicis brevis (APB) muscle with the reference electrode
4 cm distally. Compound sensory action potentials (CSAPs) were
recorded from digit 2. Stimulation was applied via non-polarizable
electrodes at the median nerve at the wrist, with the reference
electrode placed 10 cm proximally, using an isolated linear bipolar
constant-current stimulator (DS5, Digitimer Ltd., Welwyn Garden
City, UK). Temperature at the site of stimulation was monitored
and maintained greater than 32uC.
Stimulus-response curves were recorded by increasing the stimulus
intensity until the maximal compound response amplitude was
obtained. The stimulus threshold was defined as the stimulus intensity
(mA) required to produce a compound response 50% of maximal
amplitude. The stimulus-response slope was derived from the range
between 25% and 75% of maximal amplitude [21]. Strength-duration
time constant (SDTC) and rheobase were determined according to
Weiss’ Law, utilising the relationship between stimulus charge and
stimulus duration [22,23], as a marker of persistent Na
+ channel
activity [24]. In addition, latent addition protocols were utilised to
assess the threshold increase at 0.2 ms, a marker of nodal persistent
Na
+ currents as SDTC measurements may be affected by other factors
[24]. Brief 60 ms stimuli were utilised, with a conditioning stimuli set to
290% of threshold and the conditioning-test interval changed between
0.02 and 0.5 ms. Analysis was completed as in [24,25]. The recovery
cycle of excitability was assessed utilizing a paired pulse protocol, with a
supramaximal stimulus followed by a test stimulus at intervals varying
between 2.5 and 200 ms. Initially following conduction of an impulse,
it becomes more difficult to generate a subsequent impulse due to the
recovery of inactivation of transient Na
+ channels [26,27]. Refracto-
riness was calculated as the percentage increase in threshold at an
interstimulus interval of 2.5 ms [26,27]. The relative refractory period
(RRP) was determined as the first intercept on the x-axis in the
recovery cycle curve, corresponding to the interstimulus interval (ms)
when threshold change was zero [20,26]. Threshold electrotonus was
assessed utilising 100 ms subthreshold polarizing currents (40% of
threshold) in both hyperpolarizing and depolarizing directions [27],
with threshold reduction assessed between 90 and 100 ms of polarizing
current in both hyperpolarizing and depolarizing directions.
Table 1. Clinical features and patient demographics.
Patient
Age
(gender)
Single
oxaliplatin
dose
(mg/m
2)
Cumulative
oxaliplatin
dose
(mg/m
2)
Cycle
tested
OSNS/
NCI
16 1 M – – 4 1
2 25 M 85 255 3 1
34 8 F 1 0 0 2 0 0 2 1
4 60 M 85 340 4 1
5 59 M 85 340 4 1
6 41 M 85 255 3 1
7 36 M 85 340 4 1
86 2 F 1 0 0 2 0 0 2 1
98 2 M 1 0 0 2 5 2 3 1
10 61 M 80 280 3 1
11 60 M 85 340 4 1
12 35 F 130 260 2 1
13 60 F 66 415 6 1
14 59 M 85 425 5 2
15 67 F 85 510 6 2
16 69 M 100 600 6 1
17 46 M 130 650 5 1
18 61 F 53 497 6 1
doi:10.1371/journal.pone.0018469.t001
Oxaliplatin Dose Effects on Na
+ Channel Function
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All statistics were performed in SPSS (Version 18, SPSS Inc.,
Chicago, US). Results were expressed as mean 6 standard error of
the mean and statistical significance was defined as P#0.05.
Recordings were paired for each patient pre- and post-infusion.
Wilcoxon sign rank tests (two-tailed) were utilised to compare
paired recordings pre- and post-oxaliplatin within individual
patients. Mann Whitney U tests (two-tailed) were used to compare
findings within groups divided by dose level. Single oxaliplatin
dose was defined as the oxaliplatin dose infused at the time of
testing. Cumulative oxaliplatin dose was calculated as the sum
total oxaliplatin dose received in all treatment cycles including the
tested cycle. Correlations were performed using Spearman’s rank
correlation coefficients.
Results
Clinical Features
All patients reported the development of acute neuropathic
symptoms following oxaliplatin infusion (average single dose
9165m g / m
2). The most commonly reported symptom was cold-
induced paresthesia in distal upper limbs, lasting for 2 to 10 days post
infusion. The majorityofpatients displayed mildneurotoxicity(89%),
with an NCI score of 1 and an OSNS neurotoxicity score of 1,
reflecting the resolution of acute neuropathic symptoms within two
weeks. 11% of patients had an OSNS score of 2, reflecting the
persistence of neuropathic symptoms for greater than two weeks.
Further patient characteristics are detailed in Table 1.
Modulation of Na
+ Channel Function with Oxaliplatin
Infusion
Immediately following oxaliplatin infusion, refractoriness was
significantly increased in motor axons (Refractoriness Pre:
31.766.4%; Post 68.8614.5%; P#.001; Figure 1A; C), consistent
with previous findings [13,15]. Similarly, there was a trend
towards increased RRP in motor axons (Pre: 3.460.2 ms; Post:
3.960.3 ms; NS). However in contrast, strength-duration time
constant (SDTC) was unchanged following oxaliplatin treatment
(Pre: 0.39560.01 ms; Post: 0.39460.02 ms; NS; Figure 1B).
Accordingly, there were no significant changes in threshold
change at 0.2 ms as assessed using latent addition (Pre:
11.261.2%; Post: 12.561.4%; NS). In addition, other stimulus-
response and strength-duration properties, including rheobase
(Pre: 3.260.2 mA; Post: 2.660.2 mA; NS), stimulus-response
slope (Pre: 6.560.5; Post: 7.360.5; NS), and stimulus threshold
(Pre: 4.460.3 mA; Post: 4.960.3 mA; NS) were also unchanged
following oxaliplatin treatment. There were no major changes in
threshold electrotonus in hyperpolarizing (Pre: 2126.464.4%;
Post: 2125.863.8%; NS) or depolarizing directions (Pre:
45.760.9%; Post: 45.060.9%; NS), suggesting that axonal
Figure 1. Changes in Na
+ channel associated parameters post-oxaliplatin in motor axons. A) Refractoriness pre (black bars) and post
(white bars) single oxaliplatin infusion demonstrating significant change post-oxaliplatin in motor axons (Refractoriness Pre: 31.766.4%; Post
68.8614.5%; P#.001). B) Strength-duration time constant pre (black bars) and post (white bars) oxaliplatin infusion, demonstrating unchanged results
following oxaliplatin treatment (Pre: 0.39560.01 ms; Post: 0.39460.02 ms; NS). C) Inset diagram of the changes in the recovery cycle of excitability
pre- (black circles) and post-oxaliplatin infusion (white circles) for all patients, with error bars representing standard error of the mean and
refractoriness outlined by a box and an arrow demonstrating direction of change.
doi:10.1371/journal.pone.0018469.g001
Oxaliplatin Dose Effects on Na
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treatment in motor axons. Maximal CMAP amplitude also
remained unchanged post-oxaliplatin treatment (Pre: 6.76
0.7 mV; Post: 6.460.5 mV; NS). There were no significant
differences in limb temperature pre- and post-oxaliplatin infusion
(Pre: 32.160.2uC; Post: 3.260.2uC; NS). Of further relevance, all
patients in the present study received intravenous chemotherapy
through a central venous catheter rather than through a peripheral
vein, and so the temperature of the testing arm was not affected by
infusion-related issues.
Conversely to these findings in motor axons, there was a
significant reduction in refractoriness in sensory axons following
oxaliplatin treatment (Pre: 31.465.4%; Post: 21.465.5%; P,.05;
Figure 2A) in accordance with previous studies [14,15]. In
accordance with these changes, RRP was significantly reduced
(Pre: 3.960.1 ms; Post: 3.460.2 ms; P,.05). However, there were
no significant differences in SDTC (Pre: 0.5446.03 ms; Post:
0.5356.05 ms; NS; Figure 2B), rheobase (Pre: 2.360.4 mA; Post:
2.460.4 mA; NS) or stimulus threshold (Pre: 4.860.8 mA; Post:
5.260.9 mA; NS) following oxaliplatin treatment in sensory
axons. As in motor axons, markers of axonal membrane potential
remained unchanged (Threshold electrotonus hyperpolarizing Pre:
2141.467.0%; Post: 2142.868.7%; NS; TE depolarizing Pre:
51.261.6%; Post: 52.062.0%; NS). Maximal CSAP amplitude
was unchanged post-oxaliplatin (Pre: 47.3610.1 mV; Post:
44.3610.7 mV; NS).
Oxaliplatin Dose-Response Relationship
To determine the relationship of acute changes in Na
+ channel-
related parameters with oxaliplatin dose levels, comparisons were
made across different dose levels. In motor axons, single oxaliplatin
dose was significantly correlated with change in refractoriness
following infusion (Correlation coefficient=.80; P#.001; Figure 3A).
While overall there was no significant changes in SDTC following
oxaliplatin treatment, higher cumulative doses were associated with
an increase in SDTC (Correlation coefficient=.75; P#.001;
Figure 3B). Similarly, there was an association between threshold
change at 0.2 ms as assessed using latent addition and cumulative
dose (Correlation coefficient=.66; P,.05). In patients assessed at a
cumulative dose of less than 400 mg/m
2, there was also a significant
Figure 2. Changes in Na
+ channel associated parameters post-oxaliplatin in sensory axons. A) Refractoriness pre (black bars) and post
(white bars) oxaliplatin treatment (Pre: 31.465.4%; Post: 21.465.5%; P,.05), demonstrating significant reduction post-oxaliplatin in sensory axons.
B) Strength-duration time constant pre (black bars) and post (white bars) treatment (Pre: 0.5446.03 ms; Post: 0.5356.05 ms; NS), with no significant
effect post oxaliplatin treatment. C) Changes in the recovery cycle of excitability pre- (black circles) and post-oxaliplatin infusion (white circles) for all
patients, with error bars representing standard error of the mean and refractoriness outlined by a box and an arrow demonstrating direction of
change.
doi:10.1371/journal.pone.0018469.g002
Oxaliplatin Dose Effects on Na
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Change in refractoriness post-oxaliplatin was significantly correlated
with change in SDTC (Correlation coefficient=2.65; P,.05;
Figure 3C), suggesting a link between the mechanisms underlying
changes in these parameters. Despite this, the overall sensitivity of
refractoriness to change following oxaliplatin treatment was signifi-
cantly greater than that of SDTC (Table 2).
In sensory axons, the extent of change in pre-oxaliplatin
refractoriness was determined by the cumulative oxaliplatin dose
(Correlation coefficient=2.72; P,.01; Figure 4A), presumably
reflecting the development of chronic changes in sensory axonal
excitability with increasing dose. Therefore, patients with a
cumulative dose of less than 400 mg/m
2 were also assessed and
accordingly, refractoriness post-oxaliplatin infusion was signifi-
cantly correlated with SDTC post-oxaliplatin (Correlation coeffi-
cient=.67; P,.05), although again the extent of change in
refractoriness far exceeded the change in SDTC (Table 2).
Discussion
The present study represents the first assessment of the dose-
response properties of acute and cumulative oxaliplatin exposure
in human axons in vivo. Markers of transient and persistent Na
+
conductances were investigated in patients receiving neurotoxic
chemotherapy with oxaliplatin, to clarify existing in vitro data
which suggested tremendous variability between experimental
preparations. Importantly, the present study is the first to directly
compare the relationship between oxaliplatin dose and transient
and persistent Na
+ conductances, in both motor and sensory
axons. While there were significant changes in markers of Na
+
channel inactivation in both motor and sensory axons post-
oxaliplatin infusion, changes in markers of non-inactivating Na
+
conductances were relatively minor. There were significant
correlations between oxaliplatin dose level and Na
+ channel-
associated parameters, suggesting a dose-response relationship
between Na
+ channel dysfunction and oxaliplatin dose. Taken in
total, the present findings suggest that acute oxaliplatin adminis-
tration preferentially affects markers of transient Na
+ conductanc-
es, at least in the clinical setting.
Modulation of Transient and Persistent Na
+
Conductances
In human peripheral nerves, both transient and persistent Na
+
currents have been functionally identified [24,28–30]. The
transient Na
+ current contributes an estimated 98% of the total
nodal Na
+ current [31]. While the persistent Na
+ current accounts
for only 1.0–2.5% of the total Na
+ current [24,32], it exerts a
strong influence on membrane potential and axonal excitability
[28,31]. Strength-duration time constant (SDTC) provides a
surrogate marker of persistent Na
+ conductances active at
threshold [23,24], while refractoriness classically relates to
inactivation of transient Na
+ channels [27,29]. While it has been
Figure 3. Relationship of Na
+ channel-associated parameters
with oxaliplatin dose level in motor axons. A) Relationship of Na
+
channel-associated parameters with single oxaliplatin dose level in
motor axons. Patients were divided into three single dose levels with
means of 66, 85 and 105 mg/m
2. Change in refractoriness was
significantly correlated with increasing single dose (correlation coeffi-
cient=.80; P#.001). B) Correlation of cumulative oxaliplatin dose with
the change in strength-duration time constant post-oxaliplatin in motor
axons, illustrating the association of higher cumulative doses with an
increase in strength-duration time constant (Correlation coeffi-
cient=.75; P#.001). C) Relationship of changes in refractoriness
compared to changes in SDTC in motor axons. Change in refractoriness
post-oxaliplatin was significantly associated with change in SDTC post-
oxaliplatin (correlation coefficient=2.65; P,.05).
doi:10.1371/journal.pone.0018469.g003
Table 2. Sensitivity of excitability parameters to oxaliplatin
treatment.
Parameter
Resting
value
Post-
oxaliplatin
value
Percentage
difference P value
Motor axons
Refractoriness (%) 35.768 75.5621 213% P,.05
Strength-duration
time constant (ms)
0.3956.02 0.3686.02 26% P..05
Sensory axons
Refractoriness (%) 31.465 21.466 265% P,.05
Strength-duration
time constant (ms)
0.5446.03 0.5356.05 22% P..05
doi:10.1371/journal.pone.0018469.t002
Oxaliplatin Dose Effects on Na
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Nav1.6 channels [33,34], differences in channel gating and kinetic
properties may have important functional consequences.
Mechanisms of Oxaliplatin-induced Modulation of Na
+
Channel Function
As in previous studies, a different pattern of excitability change
was identified in sensory axons acutely following oxaliplatin
administration [14,15], with sensory changes qualitatively similar
to the effects of the Na
+ channel blocker tetrodotoxin [35].
Sensory and motor axons have significantly different biophysical
properties [27] which may underlie differential expression of
oxaliplatin-induced effects on recovery cycle parameters.
In motor axons, refractoriness depends on the transmission of
impulses through the neuromuscular junction [27,36]. The
neuromuscular junction may be directly affected by oxaliplatin
[8] or the ability of the neuromuscular junction to accurately
transmit impulses may be affected as a by-product of spontaneous
high frequency activity produced by oxaliplatin [5,6]. Accordingly,
the secondary effects of spontaneous activity on motor axonal
excitability may mask the primary effect of acute oxaliplatin-
induced neurotoxicity in motor axons, leading to a different
observed pattern of changes in motor axons from sensory axons.
Spontaneous activity in sensory axons could be expected to
produce a different pattern of changes due to the lack of a
neuromuscular junction. However, importantly, the extent of
oxaliplatin-induced excitability abnormalities in both motor and
sensory axons were correlated [14], suggesting that the factors
underlying acute oxaliplatin-induced abnormalities in sensory and
motor axons are linked.
In vitro studies have suggested that oxaliplatin modulates axonal
Na
+ channel inactivation properties via slowing of inactivation
kinetics or changing the voltage dependence of activation or
inactivation [7–10]. Studies in a motor neuron-like cell line
suggesting that oxaliplatin primarily affected inactivation proper-
ties of the transient Na
+ current, with no effect on the persistent
current elicited by long ramp pulses [9]. Earlier studies in an insect
experimental preparation had conversely suggested that oxalipla-
tin preferentially affected the persistent Na
+ current [11].
However, there are known differences between the responses of
insect Na
+ channels and vertebrate Na
+ channels to tetrodotoxin
and other toxins which may underlie these apparent differences
[35,37].
Perspectives for Neuroprotective Strategies
In total, results from the present study suggest that oxaliplatin
preferentially affects voltage-gated Na
+ currents with transient
inactivation kinetics. What then are the implications of these
findings for the design of neuroprotective strategies? Many local
anesthestics and antiepileptic drugs target Na
+ channel properties.
While the effects of oxaliplatin have been antagonised in vitro by
the antiepileptic drug carbamazepine [7,8], trials in oxaliplatin-
treated patients have met with mixed success [6,38]. Carbamaz-
epine affects both transient and persistent Na
+ currents and is
thought to modulate channel inactivation, with a much higher
affinity for inactivated channels [39]. However, it is possible that
an alternative mechanism of Na
+ channel antagonism will be
required to avert the development of neuropathy, such as
enhancement of slow channel inactivation rather than interaction
with fast inactivation properties, as may be observed with the
novel antiepileptic drug lacosamide [40]. The development of
more sensitive Na
+ channel modulators should inevitably provide
improved selective subtype and current type modulation of
channel function, which may prove useful in treating oxaliplatin-
induced neurotoxicity, as well as a variety of inherited and
acquired Na
+ channelopathies.
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